Material and methods
Eight genotypes of 4 most common SNPs localised in GPX1, GPX4, TXNRD2 and SEP15 were selected. Genotyping was performed in 27 triplets matched BRCA1 carriers (cases and controls were matched 1:2) as well as on pairs matched 1:1 consisting of 220 unselected breast cancer (BRCA1 excluded). Cases and controls were matched for year of birth (+/-3 years), number and location of cancer among Iº relatives , smoking -the number of pack years (+/-10%) and adnexectomy.
For group of 27 triplets matched BRCA1 carriers, all patients were carriers of one of three Polish founder BRCA1 mutation (C61G, 4153delA, 5382insC) and serum was collected 1 -2 years before tumor diagnosis. Whereas for 220 pairs of unselected breast cancer, serum was collected before treatment but during diagnosis.
The following techniques for laboratory analyses have been applied: a) sequencing on ABI310, b) TaqMan analysis (a melting-curve genotyping with fluorescence-labeled probes based on the LightCycler 480 System (Roche Applied Science), c) determination of selenium concentration in serum using ICP MS -inductively coupled plasma mass spectrometry with ± 5% accuracy (Perkin Elmer).
Pomeranian Medical University and Read Gene SA, Szczecin, Poland In both studied groups there was observed that the optimal concentration of selenium was in range 100 -120µg/l of serum independently on variants in selenoprotein coding genes. If selenium level data were combined with some selenoprotein genotypes a tendency was found that the optimal selenium level for carriers of GPX1 nCC genotype (Table. 1) is around 75µg/l of serum and for carriers of GPX1 CC the optimal selenium level is 120µg/l.
Conclusions
• Selenium, depending on Se concentration, can cause cancer or prevent against cancer.
• The effect of selenium depends on selenoprotein genotypes and concentration of selenium in the body/ diet.
• Generally the optimal concentration of selenium for BRCA1 mutation carriers and unselected breast cancer is in range 100 -120µg/l of serum.
• For women (BRCA1 mutation carriers and unselected breast cancer) with genotype nCC in GPX1 gene the optimal concentration of selenium is around 75µg/l of serum.
• The results of association studies require confirmation by a prospective observation of large groups of patients.
• Investigation on larger number of patients are needed especially valuable may be observations of women with increased risk of cancers. 
